Cipla signs pact with Novartis Pharma AG for diabetes drug Galvus
The Hindu
Drugmaker Cipla has signed a perpetual license agreement with Novartis Pharma AG (Switzerland) to manufacture
Drugmaker Cipla has signed a perpetual license agreement with Novartis Pharma AG (Switzerland) to manufacture and market diabetes drug Galvus and its combination brands from January 1, 2026.
One of the leading brands in the Dipeptidyl Peptidase-4 (DPP4) space, especially in the oral diabetic medication category, Galvus has potential to contribute significantly to its portfolio with reported sales of ₹268 crore, Cipla said citing IQVIA (MAT February 2023) numbers.
The agreement is subject to satisfaction of certain conditions precedent. During the interim Cipla will continue to market and distribute Galvus branded products. “This deal is expected to further bolster Cipla’s position in India as one of the top players in the diabetes category,” the company said in a stock exchange filing on April 10.
The Thane police have arrested two co-founders of cryptocurrency exchange platform CoinDCX in connection with an alleged fraud of Rs 71.6 lakh, officials said
Meta Chief Executive Mark Zuckerberg is building a CEO agent to help him do his job, the Wall Street Journal reported
Insurance penetration and density are often misunderstood and do not reveal how many families are insured or whether they would be financially secure if the main earning member were to die. The real issue is not reach but adequacy, as households may have life insurance but not enough cover to replace lost income, leaving them financially vulnerable.
Five top firms lose ₹1 lakh crore in market value, with HDFC Bank experiencing the largest decline of ₹56,124.48 crore.
L&T confirms 95% of its West Asia project sites are safe, while addressing logistics challenges amid ongoing regional conflicts.
Mines Ministry to auction 19 critical mineral blocks on March 23, expanding strategic resources for clean energy and technology sectors.
Mines Ministry to auction 19 critical mineral blocks on March 23, expanding strategic resources for clean energy and technology sectors.
Five top firms lose ₹1 lakh crore in market value, with HDFC Bank experiencing the largest decline of ₹56,124.48 crore.
HDFC Bank terminates three senior officials over client onboarding issues at its DIFC branch amid ethical concerns following chairman's resignation.
Air India CEO warns of potential flight cuts and reduced travel demand due to rising fuel costs amid ongoing Gulf conflict.
Options are widely used by retail traders to speculate on the value of the stock for immediate gains and such behaviour in large scale can distort the market
India achieves 1 billion tonne coal production for the second consecutive year, ensuring stable energy supply and economic growth.
Generic drugmakers in India launch affordable Semaglutide versions, targeting a $1 billion diabetes and weight loss market.